Alder, which is developing antibodies to fight migraine and arthritis, secured $38m in a 2012 venture round backed by Novo and TPG, and will use the money from the initial public offering to forward testing.
Alder BioPharmaceuticals, a US-based pharmaceutical company seeking to treat disorders including migraines and rheumatoid arthritis, has filed for an initial public offering that could raise up to $115m.
Alder raised $38m in series D funding in 2012 from investors including Novo Ventures, which acts as the corporate venturing unit of healthcare company Novo, and TPG Biotech, the life sciences investment arm of private equity firm TPG, as well as Washington Research Foundation’s venture capital unit WRF Capital and venture capital…
